Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 14 | 2016 | 347 | 1.090 |
Why?
|
| Neoplasms | 8 | 2025 | 1357 | 0.960 |
Why?
|
| Peritoneal Neoplasms | 3 | 2015 | 30 | 0.850 |
Why?
|
| General Surgery | 2 | 2023 | 212 | 0.730 |
Why?
|
| Societies, Medical | 1 | 2023 | 400 | 0.670 |
Why?
|
| Antineoplastic Agents | 5 | 2025 | 640 | 0.610 |
Why?
|
| Preoperative Care | 3 | 2019 | 200 | 0.610 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 42 | 0.530 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 90 | 0.530 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 1211 | 0.510 |
Why?
|
| Potassium Iodide | 1 | 2016 | 4 | 0.500 |
Why?
|
| Graves Disease | 1 | 2016 | 16 | 0.500 |
Why?
|
| Thyroidectomy | 1 | 2016 | 31 | 0.490 |
Why?
|
| Pancreatectomy | 7 | 2016 | 99 | 0.490 |
Why?
|
| Frailty | 1 | 2018 | 128 | 0.480 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 702 | 0.480 |
Why?
|
| Genes, p16 | 1 | 2015 | 6 | 0.450 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2015 | 13 | 0.450 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 286 | 0.430 |
Why?
|
| Hyperthermia, Induced | 2 | 2014 | 20 | 0.410 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 3 | 0.380 |
Why?
|
| Trisaccharides | 1 | 2012 | 8 | 0.380 |
Why?
|
| Cancer Vaccines | 1 | 2012 | 51 | 0.370 |
Why?
|
| Humans | 47 | 2026 | 64729 | 0.350 |
Why?
|
| Database Management Systems | 1 | 2010 | 20 | 0.320 |
Why?
|
| Female | 32 | 2026 | 33739 | 0.300 |
Why?
|
| Postoperative Complications | 5 | 2026 | 1309 | 0.300 |
Why?
|
| Carcinoma | 1 | 2009 | 130 | 0.280 |
Why?
|
| Retrospective Studies | 17 | 2023 | 6803 | 0.270 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 155 | 0.270 |
Why?
|
| Genetic Therapy | 1 | 2015 | 821 | 0.270 |
Why?
|
| Esophagectomy | 2 | 2026 | 53 | 0.270 |
Why?
|
| Treatment Outcome | 13 | 2026 | 5758 | 0.260 |
Why?
|
| Adenoma | 2 | 2007 | 68 | 0.260 |
Why?
|
| Artificial Intelligence | 1 | 2010 | 209 | 0.250 |
Why?
|
| Liver Neoplasms | 2 | 2009 | 304 | 0.250 |
Why?
|
| Male | 29 | 2026 | 30790 | 0.240 |
Why?
|
| Middle Aged | 26 | 2026 | 18106 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 461 | 0.230 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 190 | 0.230 |
Why?
|
| Adult | 13 | 2025 | 17230 | 0.220 |
Why?
|
| Injections, Intralesional | 2 | 2016 | 14 | 0.220 |
Why?
|
| Palliative Care | 1 | 2007 | 245 | 0.220 |
Why?
|
| Hepatectomy | 2 | 2019 | 63 | 0.220 |
Why?
|
| Esophageal Neoplasms | 1 | 2026 | 94 | 0.220 |
Why?
|
| Aged | 20 | 2026 | 14834 | 0.210 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 8 | 0.200 |
Why?
|
| Parathyroid Neoplasms | 1 | 2003 | 5 | 0.200 |
Why?
|
| Parathyroidectomy | 1 | 2003 | 7 | 0.200 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2003 | 34 | 0.200 |
Why?
|
| Catheter Ablation | 1 | 2005 | 154 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 797 | 0.200 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 53 | 0.190 |
Why?
|
| New England | 1 | 2023 | 269 | 0.190 |
Why?
|
| Melanoma | 2 | 2016 | 332 | 0.190 |
Why?
|
| History, 21st Century | 1 | 2023 | 178 | 0.190 |
Why?
|
| History, 20th Century | 1 | 2023 | 232 | 0.190 |
Why?
|
| Lung | 2 | 2023 | 965 | 0.170 |
Why?
|
| Laparoscopy | 3 | 2021 | 492 | 0.170 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 22 | 0.170 |
Why?
|
| Hernia, Hiatal | 1 | 2021 | 29 | 0.170 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2015 | 122 | 0.170 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2483 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 61 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2021 | 2086 | 0.160 |
Why?
|
| Databases, Factual | 4 | 2026 | 879 | 0.160 |
Why?
|
| Neoplasm Staging | 6 | 2025 | 539 | 0.160 |
Why?
|
| Survival Rate | 7 | 2010 | 847 | 0.160 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 174 | 0.150 |
Why?
|
| Spinal Fusion | 1 | 2021 | 156 | 0.150 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 39 | 0.140 |
Why?
|
| Injections, Intraperitoneal | 2 | 2015 | 46 | 0.140 |
Why?
|
| Vaccination | 1 | 2021 | 374 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2005 | 1656 | 0.140 |
Why?
|
| Pandemics | 1 | 2023 | 669 | 0.140 |
Why?
|
| Hospital Mortality | 7 | 2010 | 872 | 0.140 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2016 | 62 | 0.140 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 5562 | 0.140 |
Why?
|
| Caregivers | 1 | 2021 | 292 | 0.130 |
Why?
|
| Mice, Nude | 2 | 2015 | 286 | 0.130 |
Why?
|
| Cisplatin | 2 | 2025 | 147 | 0.130 |
Why?
|
| Lymphoscintigraphy | 1 | 2016 | 6 | 0.130 |
Why?
|
| Adrenalectomy | 2 | 2010 | 24 | 0.130 |
Why?
|
| Sentinel Lymph Node | 1 | 2016 | 12 | 0.120 |
Why?
|
| Methylene Blue | 1 | 2016 | 22 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2018 | 289 | 0.120 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 39 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 364 | 0.120 |
Why?
|
| United States | 12 | 2026 | 8041 | 0.120 |
Why?
|
| Coloring Agents | 1 | 2016 | 50 | 0.120 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 64 | 0.120 |
Why?
|
| Operative Time | 1 | 2016 | 91 | 0.120 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2016 | 7 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2016 | 142 | 0.120 |
Why?
|
| Glycolipids | 1 | 2016 | 44 | 0.120 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 219 | 0.120 |
Why?
|
| Pancreas, Exocrine | 1 | 2016 | 12 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2680 | 0.120 |
Why?
|
| Pancreatitis, Chronic | 1 | 2015 | 21 | 0.120 |
Why?
|
| Diet | 1 | 2019 | 534 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 168 | 0.110 |
Why?
|
| Random Allocation | 1 | 2015 | 200 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2015 | 130 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2015 | 140 | 0.110 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 283 | 0.110 |
Why?
|
| Hospital Information Systems | 1 | 2013 | 10 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 522 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 371 | 0.100 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2012 | 3 | 0.100 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2012 | 50 | 0.090 |
Why?
|
| Risk Factors | 8 | 2021 | 5393 | 0.090 |
Why?
|
| MCF-7 Cells | 1 | 2012 | 65 | 0.090 |
Why?
|
| Apoptosis | 2 | 2015 | 1094 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 403 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2012 | 184 | 0.090 |
Why?
|
| Quality of Life | 2 | 2010 | 1254 | 0.090 |
Why?
|
| Quality of Health Care | 2 | 2021 | 524 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2013 | 270 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 184 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1556 | 0.080 |
Why?
|
| Methionine | 1 | 2010 | 57 | 0.080 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2010 | 28 | 0.080 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2010 | 14 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2013 | 380 | 0.080 |
Why?
|
| Sarcoma | 1 | 2010 | 36 | 0.080 |
Why?
|
| Patient Simulation | 1 | 2010 | 67 | 0.080 |
Why?
|
| Inpatients | 2 | 2010 | 310 | 0.080 |
Why?
|
| Infusions, Parenteral | 1 | 2009 | 21 | 0.080 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2009 | 17 | 0.080 |
Why?
|
| Mitomycin | 1 | 2009 | 27 | 0.080 |
Why?
|
| Digestive System Diseases | 1 | 2009 | 14 | 0.080 |
Why?
|
| SEER Program | 4 | 2010 | 75 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 37 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 31 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 99 | 0.070 |
Why?
|
| Incidence | 3 | 2021 | 1409 | 0.070 |
Why?
|
| Neuroendocrine Tumors | 1 | 2009 | 20 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 53 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2009 | 97 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2015 | 903 | 0.070 |
Why?
|
| Sp1 Transcription Factor | 1 | 2008 | 21 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 285 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2016 | 58 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2010 | 350 | 0.070 |
Why?
|
| Length of Stay | 3 | 2026 | 822 | 0.070 |
Why?
|
| Emotions | 1 | 2010 | 228 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 369 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 46 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2009 | 278 | 0.070 |
Why?
|
| Prognosis | 4 | 2019 | 1770 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2010 | 47 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 1689 | 0.060 |
Why?
|
| Gastrectomy | 1 | 2007 | 39 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2007 | 77 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2007 | 81 | 0.060 |
Why?
|
| Curriculum | 1 | 2010 | 603 | 0.060 |
Why?
|
| Vinblastine | 1 | 2025 | 15 | 0.060 |
Why?
|
| Caprylates | 1 | 2025 | 15 | 0.060 |
Why?
|
| Communication | 1 | 2010 | 593 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 622 | 0.060 |
Why?
|
| Algorithms | 1 | 2010 | 1033 | 0.050 |
Why?
|
| Radiography, Interventional | 1 | 2005 | 82 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 404 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 459 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 343 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 433 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 1220 | 0.050 |
Why?
|
| Mice | 2 | 2015 | 11085 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 3745 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 128 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 91 | 0.050 |
Why?
|
| Animals | 4 | 2015 | 21292 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2010 | 810 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2003 | 126 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 2002 | 31 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2026 | 458 | 0.040 |
Why?
|
| Surgical Mesh | 1 | 2021 | 60 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2005 | 447 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2021 | 71 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 102 | 0.040 |
Why?
|
| Patient Selection | 1 | 2023 | 483 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 583 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2010 | 2603 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 655 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2021 | 151 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2009 | 130 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 989 | 0.030 |
Why?
|
| Hospitals | 1 | 2021 | 385 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2007 | 250 | 0.030 |
Why?
|
| Age Distribution | 2 | 2007 | 258 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1210 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 90 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 740 | 0.030 |
Why?
|
| Comorbidity | 2 | 2010 | 1115 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 929 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 885 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 897 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 579 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2016 | 265 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 225 | 0.030 |
Why?
|
| Swine | 1 | 2014 | 394 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 136 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 325 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 304 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 733 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2010 | 49 | 0.020 |
Why?
|
| Cetuximab | 1 | 2010 | 8 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 240 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 45 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 67 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 152 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 146 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2010 | 108 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2009 | 56 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2009 | 31 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2010 | 214 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 414 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 311 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 414 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 249 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2007 | 37 | 0.020 |
Why?
|
| Pigmentation | 1 | 2007 | 25 | 0.020 |
Why?
|
| Canada | 1 | 2007 | 152 | 0.020 |
Why?
|
| Europe | 1 | 2007 | 199 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 734 | 0.020 |
Why?
|
| Minocycline | 1 | 2007 | 28 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 2007 | 23 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 2658 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2009 | 194 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2007 | 238 | 0.020 |
Why?
|
| Adolescent | 2 | 2007 | 6291 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 745 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 4771 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 875 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2007 | 755 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2010 | 723 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2009 | 518 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 922 | 0.010 |
Why?
|
| Decision Making | 1 | 2007 | 415 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 543 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1555 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 286 | 0.010 |
Why?
|
| Massachusetts | 1 | 2008 | 2137 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 220 | 0.010 |
Why?
|
| Hospitalization | 1 | 2007 | 1384 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1572 | 0.010 |
Why?
|